Jagsonpal Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Regulatory & Legal View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹182.98

prior close

₹182.75

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+1.7% vs market

Pharmaceuticals peers, median of 157sector-1.3%+2.4% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.7

15m

-0.3

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1-0.6+1.7-1.3+2.4

Next day

+1.6+0.4+1.2-0.7+2.3

+1.2+3.1-1.8+0.3+1.0

-0.6+0.2-0.7-1.3+0.7

+1.1+1.1+0.0-0.4+1.5

-0.3-3.6+3.3-4.2+3.8

+1.1+1.5-0.4-0.5+1.6

15d

+6.0+6.5-0.5+3.8+2.2

+6.1+12.8-6.7+8.0-2.0

+8.7+15.4-6.6+9.7-1.0

+14.5+24.3-9.8+12.8+1.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals has received an assessment order from the Income Tax Department's Faceless Assessment Unit, dated March 12, 2026, for Assessment Year 2024-25. The order disallows certain expenses claimed in the company's tax return, resulting in a tax demand of Rs. 4,81,61,360 (approximately Rs. 4.82 crore) along with potential penalties. The company has stated it believes it has strong grounds to contest this and does not expect any material financial impact. It plans to file an appeal before the Appellate Authority within the prescribed timelines.

Likely market impact

Near-term negative sentiment possible due to the tax demand, but the company has signaled confidence in its appeal and minimal financial impact. Investors should watch the appeal outcome as a final adverse ruling could affect earnings and cash flows.